LLYELI LILLY & Co

NYSE lilly.com


$ 864.92 $ 15.01 (1.77 %)    

Monday, 10-Jun-2024 15:59:57 EDT
QQQ $ 464.61 $ 1.87 (0.4 %)
DIA $ 389.34 $ 0.80 (0.21 %)
SPY $ 535.72 $ 1.65 (0.31 %)
TLT $ 90.89 $ -0.61 (-0.67 %)
GLD $ 213.56 $ 1.94 (0.92 %)
$ 865
$ 858.00
$ 0.00 x 0
$ 0.00 x 0
$ 849.79 - $ 871.32
$ 431.12 - $ 871.63
3,344,394
na
781.79B
$ 0.57
$ 127.36
TBD
na
na ($ 0.01)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 04-30-2024 03-31-2024 10-Q
2 02-21-2024 12-31-2023 10-K
3 11-02-2023 09-30-2023 10-Q
4 08-08-2023 06-30-2023 10-Q
5 04-27-2023 03-31-2023 10-Q
6 02-22-2023 12-31-2022 10-K
7 11-01-2022 09-30-2022 10-Q
8 08-04-2022 06-30-2022 10-Q
9 04-29-2022 03-31-2022 10-Q
10 02-23-2022 12-31-2021 10-K
11 10-27-2021 09-30-2021 10-Q
12 08-03-2021 06-30-2021 10-Q
13 04-30-2021 03-31-2021 10-Q
14 02-17-2021 12-31-2020 10-K
15 10-28-2020 09-30-2020 10-Q
16 07-31-2020 06-30-2020 10-Q
17 05-01-2020 03-31-2020 10-Q
18 02-19-2020 12-31-2019 10-K
19 10-25-2019 09-30-2019 10-Q
20 08-02-2019 06-30-2019 10-Q
21 05-02-2019 03-31-2019 10-Q
22 02-19-2019 12-31-2018 10-K
23 11-06-2018 09-30-2018 10-Q
24 07-25-2018 06-30-2018 10-Q
25 04-27-2018 03-31-2018 10-Q
26 02-20-2018 12-31-2017 10-K
27 10-27-2017 09-30-2017 10-Q
28 07-28-2017 06-30-2017 10-Q
29 05-01-2017 03-31-2017 10-Q
30 02-21-2017 12-31-2016 10-K
31 10-28-2016 09-30-2016 10-Q
32 07-28-2016 06-30-2016 10-Q
33 04-29-2016 03-31-2016 10-Q
34 02-19-2016 12-31-2015 10-K
35 10-30-2015 09-30-2015 10-Q
36 07-30-2015 06-30-2015 10-Q
37 04-30-2015 03-31-2015 10-Q
38 02-19-2015 12-31-2014 10-K
39 10-29-2014 09-30-2014 10-Q
40 07-28-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 lilly-alzheimers-drug-receives-unanimous-11-0-vote-from-fda-panel-fda-panel-to-review-safety-and-potential-limits-of-lilly-drug-next

- Bloomberg

 whats-happening-with-eli-lilly-shares-on-monday

Eli Lilly reports detailed results from the SYNERGY-NASH phase 2 study. The trial, involving 190 patients with and without type...

 reported-saturday-lillys-tirzepatide-outperformed-placebo-in-mash-resolution-with-more-than-half-of-patients-showing-fibrosis-improvement-at-52-weeks

SYNERGY-NASH results were presented at the European Association for the Study of the Liver Congress 2024 and simultaneously pub...

 jefferies-maintains-buy-on-eli-lilly-and-co-raises-price-target-to-957

Jefferies analyst Akash Tewari maintains Eli Lilly and Co (NYSE:LLY) with a Buy and raises the price target from $925 to $957.

 over-10000-lawsuits-in-novo-nordisks-ozempic-case-assigned-to-new-judge

Judge Karen Marston takes over the high-profile Ozempic litigation involving over 10,000 lawsuits. Here's the latest.

 wall-street-reacts-to-hot-jobs-report-stocks-swing-as-traders-abandon-july-rate-cut-hopes

May labor market report: strong job gains and wage growth, reduces chances of rate cut. Interest-rate sensitive sectors underpe...

 etfs-bet-high-on-weight-loss-drugs-but-industry-observers-question-long-term-potential

New ETFs focusing on weight-loss drugs have launched. However, industry observers caution about their long-term prospects and t...

 ozempic-wegovy-create-domino-effect-as-new-products-emerge-across-industries-to-capture-new-consumer-habits

Companies from food and beverage to fitness are adapting to the increased demand for these drugs, hoping to capitalize on shift...

 eli-lillys-alzheimers-drug-donanemab-faces-fdas-adcomm-vote-next-week-on-data-risk-profile

The FDA's advisory committee will review Eli Lilly's Phase 3 study on donanemab for Alzheimer's disease on June 10....

 us-fda-advisory-panel-to-vote-on-whether-available-data-show-that-lillys-donanemab-is-effective-for-treating-alzheimers-disease-in-patients-with-mild-cognitive-impairment--mild-dementia

- Reuters

 fda-staff-reviewers-report-higher-number-of-deaths-in-donanemab-treated-participants-compared-to-placebo-deaths-not-fully-explained-by-aria-or-cerebral-hemorrhage

- Reuters

 whats-going-on-with-fattly-liver-disease-focused-madrigal-pharmaceuticals-sagimet-biosciences-shares-on-wednesday

Madrigal Pharmaceuticals and Sagimet Biosciences shares fall following Eli Lilly's presentation at the EASL Liver Congress ...

 british-agency-supports-eli-lillys-weight-loss-drug-mounjaro-diverging-from-restrictions-on-rival-novo-nordisks-wegovy

NICE recommends Eli Lilly's Mounjaro for obesity, omitting time limits applied to Novo Nordisk's Wegovy, opening new av...

 google-parent-alphabet-appoints-eli-lillys-finance-chief-ashkenazi-as-cfo

Anat Ashkenazi resigns as CFO of Eli Lilly to join Google as CFO and SVP. She will remain at Lilly until July 2024 while her su...